Processa Pharmaceuticals, Inc. (PCSA)
About Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $0
- Net income
- -$13.6M
- Total assets
- $7.8M
- Market cap
- $6.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$14.0M
- Net income
- -$13.6M
- EPS (basic)
- $-10.36
- EPS (diluted)
- $-10.36
Balance sheet
- Total assets
- $7.8M
- Current assets
- $5.7M
- Total liabilities
- $2.2M
- Current liabilities
- $2.2M
- Shareholders’ equity
- $5.6M
Cash flow
- Operating cash flow
- -$11.4M
- Investing cash flow
- -$850.0K
- Financing cash flow
- $16.6M
- Net cash flow
- $4.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $6.9M
- EPS (diluted)
- $-10.36
- Shares outstanding
- 2.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 7, 2013
Processa Pharmaceuticals, Inc. (PCSA) Stock Price
- Reported a net loss of $13.6M in FY2022.
- Trading 78% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Processa Pharmaceuticals, Inc..
Write a review
News about Processa Pharmaceuticals, Inc.
News & sentiment via Polygon.io
Processa Pharmaceuticals, Inc.: frequently asked questions
Is Processa Pharmaceuticals, Inc. an American company?
Processa Pharmaceuticals, Inc. is a US-based company headquartered in Vero Beach, Florida, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Processa Pharmaceuticals, Inc. headquartered?
Processa Pharmaceuticals, Inc. is headquartered in Vero Beach, Florida, United States.
Is Processa Pharmaceuticals, Inc. publicly traded?
Yes — Processa Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol PCSA on the NASDAQ.
What does Processa Pharmaceuticals, Inc. do?
Processa Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
